• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗产品开发中贝叶斯方法的现状:DIA贝叶斯科学工作组的调查结果与建议

The current state of Bayesian methods in medical product development: survey results and recommendations from the DIA Bayesian Scientific Working Group.

作者信息

Natanegara Fanni, Neuenschwander Beat, Seaman John W, Kinnersley Nelson, Heilmann Cory R, Ohlssen David, Rochester George

机构信息

Eli Lilly and Company, Indianapolis, IN, USA.

出版信息

Pharm Stat. 2014 Jan-Feb;13(1):3-12. doi: 10.1002/pst.1595. Epub 2013 Sep 11.

DOI:10.1002/pst.1595
PMID:24027093
Abstract

Bayesian applications in medical product development have recently gained popularity. Despite many advances in Bayesian methodology and computations, increase in application across the various areas of medical product development has been modest. The DIA Bayesian Scientific Working Group (BSWG), which includes representatives from industry, regulatory agencies, and academia, has adopted the vision to ensure Bayesian methods are well understood, accepted more broadly, and appropriately utilized to improve decision making and enhance patient outcomes. As Bayesian applications in medical product development are wide ranging, several sub-teams were formed to focus on various topics such as patient safety, non-inferiority, prior specification, comparative effectiveness, joint modeling, program-wide decision making, analytical tools, and education. The focus of this paper is on the recent effort of the BSWG Education sub-team to administer a Bayesian survey to statisticians across 17 organizations involved in medical product development. We summarize results of this survey, from which we provide recommendations on how to accelerate progress in Bayesian applications throughout medical product development. The survey results support findings from the literature and provide additional insight on regulatory acceptance of Bayesian methods and information on the need for a Bayesian infrastructure within an organization. The survey findings support the claim that only modest progress in areas of education and implementation has been made recently, despite substantial progress in Bayesian statistical research and software availability.

摘要

贝叶斯方法在医疗产品开发中的应用近年来颇受关注。尽管贝叶斯方法和计算技术取得了诸多进展,但在医疗产品开发各个领域的应用增长仍较为有限。药品信息协会(DIA)贝叶斯科学工作组(BSWG)由来自行业、监管机构和学术界的代表组成,其目标是确保贝叶斯方法得到充分理解、更广泛地被接受,并被合理应用于改善决策和提高患者治疗效果。由于贝叶斯方法在医疗产品开发中的应用范围广泛,因此成立了几个子团队,专注于患者安全、非劣效性、先验设定、比较疗效、联合建模、项目整体决策、分析工具和教育等不同主题。本文重点介绍了BSWG教育子团队最近开展的一项工作,即对参与医疗产品开发的17个组织中的统计学家进行贝叶斯方法调查。我们总结了此次调查的结果,并据此就如何在整个医疗产品开发过程中加速贝叶斯方法的应用提出建议。调查结果印证了文献中的研究发现,并提供了关于监管机构对贝叶斯方法接受程度的更多见解,以及有关组织内部对贝叶斯基础设施需求的信息。调查结果支持了这样一种观点,即尽管贝叶斯统计研究和软件可用性取得了显著进展,但最近在教育和应用领域仅取得了有限的进展。

相似文献

1
The current state of Bayesian methods in medical product development: survey results and recommendations from the DIA Bayesian Scientific Working Group.医疗产品开发中贝叶斯方法的现状:DIA贝叶斯科学工作组的调查结果与建议
Pharm Stat. 2014 Jan-Feb;13(1):3-12. doi: 10.1002/pst.1595. Epub 2013 Sep 11.
2
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis.药物安全性贝叶斯网络荟萃分析的实施与报告指南。
Pharm Stat. 2014 Jan-Feb;13(1):55-70. doi: 10.1002/pst.1592. Epub 2013 Aug 30.
3
The current state of Bayesian methods in nonclinical pharmaceutical statistics: Survey results and recommendations from the DIA/ASA-BIOP Nonclinical Bayesian Working Group.非临床药物统计学中贝叶斯方法的现状:DIA/ASA-BIOP非临床贝叶斯工作组的调查结果与建议
Pharm Stat. 2021 Mar;20(2):245-255. doi: 10.1002/pst.2072. Epub 2020 Oct 6.
4
Bayesian methods for design and analysis of safety trials.用于安全性试验设计与分析的贝叶斯方法。
Pharm Stat. 2014 Jan-Feb;13(1):13-24. doi: 10.1002/pst.1586. Epub 2013 Jul 30.
5
Bayesian methods in medical product development and regulatory reviews.医疗产品开发与监管审评中的贝叶斯方法。
Pharm Stat. 2014 Jan-Feb;13(1):1-2. doi: 10.1002/pst.1608. Epub 2014 Jan 10.
6
The NCI All Ireland Cancer Conference.美国国家癌症研究所全爱尔兰癌症会议。
Oncologist. 1999;4(4):275-277.
7
Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).第二届理论与产业研讨会会议录(2007年6月12日至14日,奥地利维也纳埃尔温·薛定谔研究所)
J Phys Condens Matter. 2008 Feb 13;20(6):060301. doi: 10.1088/0953-8984/20/06/060301. Epub 2008 Jan 24.
8
Bayesian statistics in medical devices: innovation sparked by the FDA.医疗器械中的贝叶斯统计:由美国食品药品监督管理局引发的创新。
J Biopharm Stat. 2011 Sep;21(5):871-87. doi: 10.1080/10543406.2011.589638.
9
A fully Bayesian multivariate approach to before-after safety evaluation.一种完全贝叶斯多元方法在前后安全性评估中的应用。
Accid Anal Prev. 2010 Jul;42(4):1118-27. doi: 10.1016/j.aap.2009.12.026.
10
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.临床肿瘤进展 2011:美国临床肿瘤学会癌症进展年度报告。
J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

引用本文的文献

1
Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers.为什么贝叶斯临床试验如此之少?医学研究人员对贝叶斯统计和传统统计的解读能力。
Ther Innov Regul Sci. 2023 May;57(3):426-435. doi: 10.1007/s43441-022-00482-1. Epub 2022 Dec 10.
2
Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.在转移性结直肠癌的早期随机对照试验中,使用历史试验数据构建混合对照臂。
Commun Med (Lond). 2022 Jul 15;2:90. doi: 10.1038/s43856-022-00155-y. eCollection 2022.
3
Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development.
为什么没有更多的贝叶斯临床试验?药物研发医学研究人员感知的障碍和教育偏好。
Ther Innov Regul Sci. 2023 May;57(3):417-425. doi: 10.1007/s43441-021-00357-x. Epub 2022 Jan 3.
4
Performance of Hamiltonian Monte Carlo and No-U-Turn Sampler for estimating genetic parameters and breeding values.汉密尔顿蒙特卡罗法和无回转抽样器在估计遗传参数和育种值中的性能。
Genet Sel Evol. 2019 Dec 10;51(1):73. doi: 10.1186/s12711-019-0515-1.